Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 50,316 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignancies Clear all
Completed No phase listed Observational Accepts healthy volunteers

Assessing Urinary Hormones in Female Cancer Survivors

NCT03197532
View directory record Official record
Conditions
Effects of Chemotherapy
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Not applicable Interventional

Acupuncture Intervention for AYA With Cancer

NCT03516799
View directory record Official record
Conditions
Palliative Care
Interventions
Acupuncture
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years to 24 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 23, 2026, 6:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Refining and Testing the Electronic Social Network Assessment Program (eSNAP)

NCT03026699
View directory record Official record
Conditions
Brain Cancer
Interventions
eSNAP, Questionnaires
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)

NCT03391232
View directory record Official record
Conditions
Colorectal Cancer
Interventions
PolyPEPI1018 CRC Vaccine
Biological
Lead sponsor
Treos Bio Zrt
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Not applicable Interventional

Young Adult Latino Testicular Cancer Survivors: a Pilot Study of Goal-Focused Emotion Regulation Therapy (GET)

NCT07615998
View directory record Official record
Conditions
Testicular Cancer
Interventions
Goal-focused Emotion-regulation Therapy
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Not listed Phase 2 Interventional

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

NCT02560298
View directory record Official record
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Recurrent Anal Canal Carcinoma, Stage IIIB Anal Canal Cancer, Stage IV Anal Canal Cancer
Interventions
Capecitabine, Carboplatin, Cisplatin, Fluorouracil, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

NCT00589563
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
Interventions
anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Phoenix, Arizona • Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 23, 2026, 6:14 AM EDT
Completed No phase listed Observational

Visualase Visualization Database (VIVID-1)

NCT03489187
View directory record Official record
Conditions
Epilepsy, Tumor, Other
Interventions
Visualase Thermal Therapy System
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
Not listed
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Interventions
Oregovomab, Niraparib
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of the Enhanced Recovery After Surgery System for Colorectal Surgery

NCT02997293
View directory record Official record
Conditions
ColoRectal Cancer and Inflammatory Bowel Disease
Interventions
Enhanced Recovery protocol
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Not listed Not applicable Interventional

Ultrasound vs. Predetermined Distance Techniques for Paravertebral Nerve Block in Patients Having Breast Surgery

NCT01217593
View directory record Official record
Conditions
Mastectomy, Breast Neoplasms
Interventions
ultrasound, predetermined distance
Procedure
Lead sponsor
Ochsner Health System
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Oct 23, 2026, 6:14 AM EDT
Terminated Phase 1 Interventional

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

NCT02833701
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Ascorbic Acid, Bevacizumab, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Dietary Supplement · Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 23, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

NCT04426201
View directory record Official record
Conditions
COVID-19, Lymphocytopenia
Interventions
CYT107, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Not applicable Interventional

Comparison of Screening Tests in Detecting Cervical Neoplasia

NCT00039312
View directory record Official record
Conditions
Cervical Cancer
Interventions
Papanicolaou test, cytology specimen collection procedure, annual screening, colposcopic biopsy, comparison of screening methods
Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

NCT03036930
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Not applicable Interventional

Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast Cancer

NCT06671730
View directory record Official record
Conditions
Breast Cancer Survivor
Interventions
8-Week Telehealth-based Occupational Therapy Program
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

NCT03465592
View directory record Official record
Conditions
Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood
Interventions
Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Months to 40 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
4
States / cities
St. Petersburg, Florida • Baltimore, Maryland • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation

NCT04229992
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Magnesium glycinate, Placebo
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 23, 2026, 6:14 AM EDT
Terminated Phase 1 Interventional

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

NCT06304636
View directory record Official record
Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Descartes-15
Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892
View directory record Official record
Conditions
Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Berzosertib, Gemcitabine, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

NCT02352844
View directory record Official record
Conditions
Solid Malignancy, Solid Tumor
Interventions
Everolimus
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Letrozole for Lymphangioleiomyomatosis

NCT01353209
View directory record Official record
Conditions
Lymphangioleiomyomatosis
Interventions
Letrozole, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Stanford, California • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 23, 2026, 6:14 AM EDT